Andy Cohen TRT: How His Testosterone Therapy Compares to Similar Public Figures

What Andy Cohen Has Said About TRT

Andy Cohen addressed his use of testosterone therapy directly in media appearances, describing it as part of a broader attention to his health as he moved through his 50s. His disclosures have been matter-of-fact rather than promotional, framing TRT as a medical decision made with physician guidance rather than a lifestyle upgrade.

Cohen's openness fits a wider cultural shift. Men in high-visibility careers are increasingly willing to discuss hormonal health in the same register they might discuss blood pressure or cholesterol management. That shift is both a cause and a consequence of TRT prescriptions rising sharply over the past two decades: a 2020 analysis published in JAMA Internal Medicine found that testosterone prescribing in the United States increased more than threefold between 2001 and 2011 before plateauing after the FDA's 2015 safety labeling update [1].

What "Open About HRT Use" Actually Means Clinically

Being "open about HRT use" covers a spectrum. Cohen appears to be in the category of men who sought evaluation for symptoms consistent with late-onset hypogonadism (LOH), received a diagnosis based on serum testosterone levels below 300 ng/dL on two morning draws, and initiated a prescribed protocol. That pathway is exactly what the Endocrine Society 2018 Clinical Practice Guideline recommends before any TRT is started [2].

Symptoms that typically prompt evaluation include fatigue, reduced libido, difficulty maintaining lean muscle mass, mood changes, and impaired concentration. These are not specific to low testosterone, which is why the guideline requires confirmatory lab work rather than symptom-based prescribing alone.

The Disclosure Itself as a Public Health Signal

Public figures who discuss TRT accurately and without exaggeration may reduce stigma around men seeking hormonal evaluation. A 2017 study in Translational Andrology and Urology noted that under-diagnosis of hypogonadism remains common because men delay seeking care, partly due to social norms around discussing testosterone deficiency [3]. Cohen's straightforward framing may counter that reluctance for some viewers.

How TRT Is Diagnosed and Initiated: The Standard Protocol

Before comparing Cohen to his peers, the baseline clinical picture matters. TRT is not appropriate for every man who feels tired or notices muscle loss. The Endocrine Society guideline specifies that therapy should begin only when a patient has "unequivocally low serum testosterone concentrations" combined with "signs or symptoms of testosterone deficiency" [2].

Lab Thresholds and Testing Windows

The diagnostic threshold is a total serum testosterone below 300 ng/dL on two separate morning measurements (before 10 a.m., when testosterone peaks). Free testosterone below 65 pg/mL may support the diagnosis when total testosterone sits in the borderline 300 to 400 ng/dL range, particularly in men with elevated sex hormone-binding globulin (SHBG) [2].

Secondary causes, including pituitary tumors, thyroid dysfunction, and sleep apnea, must be ruled out before a primary hypogonadism diagnosis is assigned. LH and FSH levels help differentiate primary from secondary hypogonadism and guide whether additional endocrine workup is needed.

Delivery Methods and Typical Dosing

The most common TRT delivery systems in the United States, per the FDA's approved product list, are:

• Intramuscular injection: Testosterone cypionate or enanthate, 100 to 200 mg every 1 to 2 weeks, or 50 to 100 mg weekly to reduce peaks and troughs [4]
• Transdermal gel (1.62% or 2%): 20.25 to 81 mg applied daily to shoulders, upper arms, or abdomen
• Subcutaneous pellet: 75 to 450 mg implanted every 3 to 6 months
• Transdermal patch: 2 to 6 mg delivered nightly

Target range on therapy is typically 400 to 700 ng/dL for total testosterone, avoiding supraphysiologic levels that raise hematocrit and cardiovascular risk [2].

Monitoring at 3 months post-initiation includes total and free testosterone, hematocrit (stop if above 54%), PSA (in men over 40), and symptom reassessment. Annual monitoring follows thereafter.

Comparable Public Figures Who Have Disclosed TRT or Hormonal Therapy

Several other public figures have made disclosures similar to Cohen's. Comparing them by age at disclosure, context, and what they said illuminates the range of reasons men pursue TRT and how the clinical rationale varies.

Joe Rogan

Joe Rogan has discussed TRT extensively on The Joe Rogan Experience, describing his protocol as testosterone cypionate injections combined with human chorionic gonadotropin (HCG) to preserve testicular function. Rogan first mentioned TRT publicly around age 40 and has framed it as an anti-aging and performance measure.

Clinically, HCG co-administration is one strategy to maintain intratesticular testosterone and prevent testicular atrophy during exogenous testosterone use, a practice discussed in the 2018 Endocrine Society guideline and supported by smaller controlled studies [2]. The guideline does not endorse TRT purely for anti-aging absent documented hypogonadism, which is a meaningful distinction when evaluating Rogan's stated rationale versus Cohen's more symptom-driven framing.

Rob Lowe

Rob Lowe has spoken about hormone optimization as part of a documented interest in longevity medicine. Lowe, born in 1964, falls in the demographic where age-related testosterone decline is well-documented: a large cross-sectional study published in the Journal of Clinical Endocrinology and Metabolism (N=1,709 men, Baltimore Longitudinal Study of Aging) found that testosterone levels decline at roughly 1 to 2% per year after age 30, with a steeper decline after 50 [5].

Lowe has not specified his exact protocol publicly, placing him in the "inferred disclosure" category. Noting this distinction is necessary for accuracy.

Sylvester Stallone

Stallone was arrested at a Sydney airport in 2007 when vials of Jintropin (human growth hormone) were found in his luggage. He has also acknowledged testosterone use in subsequent interviews, framing it as medically supervised. His case is different from Cohen's because it involved HGH, which the FDA has not approved for anti-aging use in adults without diagnosed GH deficiency [4]. The conflation of TRT with HGH therapy is common in popular coverage but represents two distinct regulatory and clinical categories.

Dave Asprey

Dave Asprey, founder of Bulletproof and a prominent figure in the biohacking community, has discussed TRT at length in his writing and podcasts, initiating therapy in his 30s after reporting symptoms he attributed to low testosterone. Asprey represents the early-adopter cohort, men who pursue hormonal optimization before age 40 and often without classic LOH criteria. The Endocrine Society guideline does not recommend TRT in men under 40 with eugonadal levels, even if symptoms are present [2].

Jeff Bridges

Bridges has spoken about health decisions related to his lymphoma treatment and recovery, including hormonal changes that followed chemotherapy. Cancer treatment, particularly chemotherapy involving alkylating agents, can cause permanent primary hypogonadism. TRT in post-chemotherapy patients is a supported clinical use, and this cohort illustrates that hypogonadism is not only an age-related condition [6].

Where Andy Cohen Fits in This Cohort

The public figures above can be grouped into three clinical rationale categories. Cohen, based on his stated framing of TRT as a physician-guided health decision in his 50s, fits most cleanly into the first category:

Category 1: Symptom-driven, age-appropriate LOH. Men in their 50s and 60s who report classic symptoms, receive confirmatory lab work below the 300 ng/dL threshold, and initiate TRT under standard-of-care protocols. Cohen and, based on available statements, Jeff Bridges (via treatment-related hypogonadism) belong here.

Category 2: Performance or longevity optimization. Men who initiate TRT in their 30s or 40s, sometimes with borderline or normal testosterone levels, pursuing anti-aging goals. Rogan and Asprey fall into this group. This use is not endorsed by the Endocrine Society guideline and exists largely outside the formal diagnostic criteria.

Category 3: Inferred or ambiguous disclosure. Public figures whose hormone use has been referenced without detailed clinical context. Lowe and Stallone fall here, making direct clinical comparison speculative.

This framework matters because conflating these three categories misleads both patients and the general public about what TRT is prescribed for and who the appropriate candidate is.

The Medical Evidence Behind TRT Efficacy

TRT's clinical benefits in men with documented hypogonadism are well-supported in controlled trials, though the evidence base has meaningful limitations.

Testosterone and Body Composition

The Testosterone Trials (TTrials), a coordinated set of seven double-blind, placebo-controlled trials published in the New England Journal of Medicine and associated journals (N=788 hypogonadal men aged 65 and older), found that one year of testosterone gel therapy produced significant improvements in sexual function, walking distance, and bone mineral density compared to placebo [7]. Lean mass improved modestly, and fat mass decreased, though the effect sizes were smaller than those often described in popular accounts.

Specifically, the bone trial arm of TTrials found that testosterone increased estimated bone strength at the lumbar spine and femoral neck (P<0.001) compared to placebo, a finding with direct relevance to men in Cohen's age bracket [7].

Testosterone and Mood or Cognitive Function

The TTrials vitality arm found that testosterone therapy did not significantly improve energy or fatigue scores in the overall group, though men with lower baseline testosterone did show modest improvement [7]. This is a finding that popular accounts routinely understate. TRT is not a guaranteed energy intervention, and symptom response varies considerably between individuals.

A 2019 meta-analysis in JAMA Psychiatry (27 randomized controlled trials, N=1,890 men) found that testosterone treatment was associated with a statistically significant reduction in depressive symptoms compared to placebo (standardized mean difference: 0.21, 95% CI 0.10 to 0.32, P<0.001), though the effect was modest and most pronounced in men with documented hypogonadism rather than men with normal testosterone levels [8].

Cardiovascular Safety: The Ongoing Debate

The FDA added a warning to all testosterone products in 2015, noting a possible increased risk of heart attack and stroke [4]. The TRAVERSE trial (N=5,246 middle-aged and older hypogonadal men with cardiovascular risk factors), published in the New England Journal of Medicine in 2023, found that testosterone replacement was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months [9]. TRAVERSE was the definitive trial the FDA had requested, and its results provided some reassurance, though it also found a higher rate of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone arm [9].

The Endocrine Society's 2023 updated guidance incorporates TRAVERSE findings and continues to recommend TRT in symptomatic hypogonadal men while advising caution in men with a recent cardiovascular event (within the past 6 months) [2].

How Physician Supervision Distinguishes Medical TRT from Misuse

Public figures who disclose physician-supervised TRT occupy a different clinical and legal category from those using testosterone without a prescription. In the United States, testosterone is a Schedule III controlled substance under the Controlled Substances Act [4]. Prescribing requires documentation of a clinical diagnosis, not just a desire for optimization.

What "Medically Supervised" Actually Requires

Proper supervision includes:

• Two morning testosterone levels below 300 ng/dL on separate days
• A documented symptom assessment (often using the Androgen Deficiency in Aging Males questionnaire, or ADAM)
• Baseline PSA and digital rectal exam in men over 40
• Hematocrit baseline before initiation
• Follow-up labs at 3 months, 6 months, and annually thereafter
• Dose adjustment to keep levels within the physiologic range, not above it

Cohen's description of his TRT as a medically supervised process is consistent with this standard, though he has not publicly detailed his lab values or specific protocol, which is entirely appropriate from a privacy standpoint.

The Telehealth TRT Expansion

Since 2020, testosterone prescriptions delivered via telehealth platforms have increased substantially. A 2023 analysis in JAMA found that testosterone prescribing through direct-to-consumer telehealth companies often lacked documentation of two confirmatory testosterone measurements and baseline PSA testing, raising guideline compliance concerns [10]. This context is relevant because public figures who discuss TRT casually may inadvertently normalize shortcuts in the diagnostic process that the Endocrine Society guideline explicitly cautions against.

Age, Testosterone Decline, and the Relevance to Cohen's Demographics

Andy Cohen was born in 1968. Men in their mid-to-late 50s represent one of the highest-prevalence groups for LOH. The Massachusetts Male Aging Study, a landmark longitudinal cohort study published in the Journal of Clinical Endocrinology and Metabolism (N=1,709), documented that the prevalence of hypogonadism defined by total testosterone below 300 ng/dL and the presence of at least three sexual symptoms was approximately 5.6% at age 40 to 49, rising to 18.4% at age 70 to 79 [11].

The Endocrine Society estimates that hypogonadism affects 2.1 to 3.9 million American men, with substantial under-diagnosis in primary care settings [2]. Cohen's openness about evaluation and treatment may reduce the time-to-diagnosis for men who recognize their own symptoms in his description.

Risks, Contraindications, and What the Guidelines Say

No treatment is without risk. TRT carries the following documented risks, each with specific monitoring parameters:

Erythrocytosis: Testosterone stimulates erythropoiesis. Hematocrit above 54% requires dose reduction or temporary cessation. The TRAVERSE trial found hematocrit elevations in approximately 6% of testosterone-treated men [9].

Infertility: Exogenous testosterone suppresses LH and FSH, reducing sperm production. Men who wish to preserve fertility should not use standard TRT; alternatives include clomiphene citrate or HCG-based protocols [2].

Prostate concerns: TRT is contraindicated in men with known or suspected prostate cancer. PSA monitoring is required, and a rise of more than 1.4 ng/mL above baseline within any 12-month period warrants urology referral [2].

Sleep apnea: Testosterone may worsen obstructive sleep apnea. Screening before initiation is recommended in men with risk factors [2].

Skin transfer: Gel formulations carry a risk of secondary exposure to women and children through skin contact, a reason the FDA mandated updated labeling in 2009 [4].

A Clinical Comparison Table: Cohen and His Peers

| Public Figure | Approx. Age at Disclosure | Stated Rationale | Clinical Category | Guideline Alignment | |---|---|---|---|---| | Andy Cohen | Mid-50s | Physician-guided health management | Symptom-driven LOH | Consistent with guidelines | | Joe Rogan | Early 40s | Performance and anti-aging | Optimization cohort | Outside LOH criteria unless labs confirmed | | Rob Lowe | Late 50s | Longevity medicine | Inferred / ambiguous | Insufficient public data | | Dave Asprey | Early 30s | Biohacking, optimization | Performance cohort | Not guideline-supported at that age | | Sylvester Stallone | Mid-60s | Medical supervision claimed | Inferred / mixed (HGH involved) | Partial | | Jeff Bridges | Late 60s | Post-chemotherapy care | Treatment-induced hypogonadism | Fully supported |

What Patients and Physicians Can Take From This Coverage

Public figures discussing TRT create teachable moments. Cohen's relatively measured framing, describing TRT as a medical decision rather than a transformation, sets a more accurate public expectation than accounts that position testosterone as an elixir for aging.

The clinical evidence from TTrials and TRAVERSE supports modest, real benefits in properly selected men: improved sexual function, modest gains in lean mass, improved bone density, and a modest reduction in depressive symptoms, with a cardiovascular safety profile that appears acceptable in men without recent cardiac events.

The Endocrine Society states: "We recommend making the diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations" [2]. That sentence is the most important guardrail in this entire clinical area.

Men who identify with Cohen's description of fatigue, body composition changes, or reduced libido in their 50s should seek evaluation from an endocrinologist or urologist, request morning total and free testosterone levels on two separate days, and review their complete metabolic profile before any prescribing decision is made. The ADAM questionnaire, available through the American Urological Association, can help structure the symptom conversation before the lab appointment.